New York City-based plastic surgeon Sachin Shridharani, MD, is now a member of Soliton’s Scientific Advisory Board. Soliton is a medical device company with a proprietary rapid acoustic pulse (RAP) technology used in laser tattoo removal and currently in trials for cellulite reduction.
Dr. Shridharani is the founder of LUXURGERY in Manhattan. He has co-authored more than 200 peer-reviewed articles, textbook chapters and abstracts on the topics of cosmetic and reconstructive surgery in respected medical journals domestically and internationally, including the Journal of the American Medical Association (JAMA) and Plastic and Reconstructive Surgery. Dr. Shridharani completed his training in plastic and reconstructive surgery at Johns Hopkins Hospital, where he served as chief resident, and completed an aesthetic plastic surgery fellowship at Manhattan Eye, Ear and Throat Hospital.
"Dr. Shridharani is an extremely talented and accomplished medical professional, and we are elated to have him join our Scientific Advisory Board. As Soliton plans to include high-quality plastic surgery offices in the U.S. commercialization of our RAP device, his extensive experience in aesthetic plastic surgery and leadership in innovative cosmetic practices will prove invaluable," said Christopher Capelli, MD, founder, president and CEO of Soliton.
"There is a significant unmet demand for a noninvasive, painless treatment for cellulite that is effective and has no bruising and minimal to no patient downtime," said Dr. Shridharani. "I feel Soliton's technology has tremendous opportunity once it is approved for this indication. The mechanism of action appears to be unique, and I am excited to work with the company on other indications this technology may be able to address."
